Showing results (111-120 of 160) with videos related to
Sort By:
Pageof 16
BMC Cancer|November 18, 2020
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumoursYvonne L E Ang, Gwo Fuang Ho, Ross A Soo, et al.The Lancet. Oncology|March 17, 2018
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyMarina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, et al.Lung Cancer (Amsterdam, Netherlands)|April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerSolange Peters, Alice T Shaw, Benjamin Besse, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER TrialRoss A Soo, Urania Dafni, Ji-Youn Han, et al.Lung Cancer (Amsterdam, Netherlands)|July 24, 2020
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC studyMarina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, et al.The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.Future Oncology (London, England)|October 3, 2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancerBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN StudyBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.Plos One|July 8, 2014
Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cellsBee Luan Khoo, Majid Ebrahimi Warkiani, Daniel Shao-Weng Tan, et al.EMBO Molecular Medicine|June 1, 2018
Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancerDana Wai Yi Tsui, Muhammed Murtaza, Alvin Seng Cheong Wong, et al.Pageof 16